- Home
- ELTX
as of 02-18-2026 2:52pm EST
$8.83
+$0.24
+2.79%
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
| Founded: | 2011 | Country: | US |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 134.1M | IPO Year: | 2014 |
| Target Price: | $13.00 | AVG Volume (30 days): | 133.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | 38.94 |
| 52 Week Low/High: | $4.60 - $12.62 | Next Earning Date: | 01-01-0001 |
| Revenue: | $2,301,000 | Revenue Growth: | -91.87% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -37155000.0 | FCF Growth: | N/A |
AI-Powered ELTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 65.77%
65.77%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Elicio Therapeutics Inc. News
ELTX Breaking Stock News: Dive into ELTX Ticker-Specific Updates for Smart Investing
Compare ELTX vs Leading Stocks
See how ELTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELTX Elicio Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.